KRAS (shortened name for the gene Kirsten RAt Sarcoma viral oncogene homolog) mutations are associated in a number of malignancies including:
Several germline KRAS mutations have also been found to be associated with some syndromes such as:
The gene provides instructions for a protein called K-Ras, which is part of a signaling pathway (RAS/MAPK pathway), instructing the cell to grow and divide, or to mature and take on specialized functions (i.e. differentiate).
- 1. Jo SJ, Kim SH. Association between oncogenic RAS mutation and radiologic-pathologic findings in patients with primary rectal cancer. (2019) Quantitative imaging in medicine and surgery. 9 (2): 238-246. doi:10.21037/qims.2018.12.10 - Pubmed
- 2. Etay Ziv, Joseph P. Erinjeri, Hooman Yarmohammadi, F. Edward Boas, Elena N. Petre, Song Gao, Waleed Shady, Constantinos T. Sofocleous, David R. Jones, Charles M. Rudin, Stephen B. Solomon. Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. (2016) Radiology. 282 (1): 251-258. doi:10.1148/radiol.2016160003 - Pubmed
- 3. Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. (2008) The Journal of molecular diagnostics : JMD. 10 (6): 493-5. doi:10.2353/jmoldx.2008.080105 - Pubmed 03 - Pubmed